<DOC>
	<DOCNO>NCT00405743</DOCNO>
	<brief_summary>Patients refractory relapse hematologic malignancy receive CP-4055 intravenously ( IV ) Day 1-5 every three week complete response disease worsening/progressing</brief_summary>
	<brief_title>A Phase I/II Study CP-4055 Patients With Refractory/Relapsed Hematologic Malignancies</brief_title>
	<detailed_description>This multicentre clinical study conduct USA Europe . It open label , dose escalation study design characterize safety , tolerability , pharmacokinetics ( PK ) , efficacy CP-4055 single agent administer 2 hour intravenous ( IV ) continuous IV ( CIV ) infusion administer daily 5 day 21-day cycle , either alone idarubicin IV , patient refractory/relapsed hematologic malignancy either fail potentially curative therapy consider unsuitable standard therapy . In second phase study efficacy single agent CP-4055 patient AML may assess . It intend patient receive minimum two cycle therapy absence unacceptable toxicity significant disease progression .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>ARM A B : Phase I CP4055 single agent 1 . Patients must relapsed/refractory leukemias standard therapy anticipate result durable response fail potentially curative therapy , refuse consider unsuitable standard therapy ARM C : CP4055 combination idarubicin 1 . Patients relapsed/refractory AML standard therapy anticipate result durable response fail potentially curative therapy , refuse consider unsuitable standard therapy ARM A , B , C : CP4055 single agent and/or combination idarubicin 2 . Patients must 18 year age old 3 . Patients must ECOG performance status ( PS ) 0 2 . See Appendix 3 4 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must negative serum urine pregnancy test within 2 week prior begin treatment study . Nursing patient exclude . Male female patient must use acceptable contraceptive method duration time study , male also 3 month last CP4055 dose 5 . Patients must capable understand comply parameter outline protocol , able willing sign write informed consent form 6 . In absence rapidly progress disease , interval prior treatment time study drug administration least 2 week cytotoxic agent , least 5 halflives noncytotoxic agent . 7 . Patients must follow clinical laboratory value : Serum creatinine less equal 1.5 x institutional upper limit normal ( ULN ) Total bilirubin less equal 1.5 x ULN unless consider due Gilbert 's syndrome Alanine aminotransferase ( ALT ) ( SGPT ) , aspartate aminotransferase ( AST ) ( SGOT ) less equal 2.5 x ULN unless consider due organ leukemic involvement Phase II 1 . Patients confirm diagnosis AML receive cytotoxic chemotherapy 2 7 . Identical inclusion criterion nos . 2 7 phase I Phase I AND II 1 . A history allergic reaction sensitivity attribute compound similar chemical biologic composition CP4055 , i.e. , araC and/or egg 2 . Known positive status human immunodeficiency virus ( HIV ) hepatitis B C 3 . Pregnant nursing patient exclude 4 . Uncontrolled intercurrent illness 5 . Active heart disease 6 . Patients receive standard investigational cytotoxic treatment hematologic malignancy maximum 5 g hydroxyurea maximum 5 day cycle 1 therapy 7 . Any medical condition opinion investigator place patient unacceptably high risk toxicity Exclusion criterion . 8 applies arm C : 8 . Patients hypersensitivity idarubicin component product , and/or anthracyclines anthracenediones</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>CP-4055</keyword>
	<keyword>ELACYTâ„¢</keyword>
	<keyword>Cancer</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>AMM</keyword>
	<keyword>CLL</keyword>
	<keyword>CML</keyword>
	<keyword>CMML</keyword>
	<keyword>MDS</keyword>
</DOC>